Here, we report the first paediatric case series of the use of miransertib in two children with severe PIK3CA-related overgrowth spectrum, one with CLOVES variant and one with facial infiltrating lipomatosis with hemimegalencephaly. This evidence concerns the gene PIK3CA and hemimegalencephaly.